Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Journey Medical Corporation (DERM)
Last journey medical corporation earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.dermira.com
Company Research
Source: GlobeNewswire
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the launch of and the first prescriptions filled for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults. Emrosi is available by prescription at specialty pharmacy chains. Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, said, “We are thrilled that the initial distribution to pharmacies is ongoing and the first Emrosi prescriptions have been filled. Rosacea is a challenging
Show less
Read more
Impact Snapshot
Event Time:
DERM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DERM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DERM alerts
High impacting Journey Medical Corporation news events
Weekly update
A roundup of the hottest topics
DERM
News
- Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in DermatologyGlobeNewswire
- What Makes Journey Medical Corporation (DERM) a Good Investment? [Yahoo! Finance]Yahoo! Finance
- Journey Medical Corp (DERM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
DERM
Earnings
- 11/12/25 - Beat
DERM
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 9/26/25 - Form 8-K
- DERM's page on the SEC website